Background {#Sec1}
==========

Dairy products are major components of daily diet and due to their abundant nutrient elements such as protein, fat, minerals and vitamins, they are listed as core parts of dietary recommendation worldwide \[[@CR1]\]. The proportion of dairy consumption was steadily increasing in several countries such as Japan since the past few decades \[[@CR2]\]. Due to the large amount of dairy products intake in our daily life and their complex composition, the emerging role of dairy products has draw researchers' attention extensively in public health.

It was universally acknowledged that dairy products intake was closely related to certain health issues. On the one hand, nutrients from dairy products were beneficial for chronic diseases such as cancer. For instance, casein was proved to have potential antimutagenic \[[@CR3]\] and anticarcinogenic properties \[[@CR4]\], while whey protein hydrolysate was demonstrated to protect against chemical-induced mammary tumor in rats \[[@CR5]\]. On the other hand, some studies drew opposite conclusions. Park et al. confirmed that the milk protein casein promoted the proliferation of prostate cancer cells through in vitro assay \[[@CR6]\]. Kroenke et al. harbored the view that high-fat dairy intake was associated with poor prognosis after breast cancer diagnosis, however no significant effect was found with respect to low-fat dairy intake \[[@CR7]\]. Yang et al. demonstrated that among men with non-metastatic prostate cancer, post diagnostic dairy products intake increased prostate cancer-specific mortality risk and all-cause mortality risk \[[@CR8]\]. In the aspect of cancer incidence risk, Huncharek et al. stated that higher consumption of milk or dairy products reduced colon cancer incidence risk \[[@CR9]\], while Faber et al. suggested that dairy products increased risk of ovarian cancer modestly \[[@CR10]\].

A few studies have conducted meta-analyses to investigate the correlation between dairy products intake and cancer incidence risk in colorectal \[[@CR11]\], prostate \[[@CR12]\], pancreatic \[[@CR13]\], gastric \[[@CR14]\] and ovarian cancers \[[@CR15]\], nevertheless the relationship between dairy products intake and cancer mortality risk was diverse and inconsistent across individual studies, which has not been discussed systematically yet. Therefore, we conducted the meta-analysis to comprehensively explore this issue.

Materials and methods {#Sec2}
=====================

Literature search {#Sec3}
-----------------

This meta-analysis was designed, conducted and reported according to PRISMA statements \[[@CR16]\]. Systematic literature search was conducted in PubMed and EMBASE database up to May 2016. The following searching strategy was adopted in PubMed: "Dairy Products" \[Mesh\] AND "Neoplasms" \[Mesh\] AND ("survival" OR "mortality" OR "death" OR "HR" OR "RR" OR "OR" OR "hazard ratio" OR "relative risk" OR "odds ratio"), and similar strategy was adopted in EMBASE: 'dairy' AND ('neoplasms' OR 'neoplasia' OR 'cancer' OR 'tumor'OR 'tumour') AND ('survival' OR 'mortality' OR 'death' OR 'hr' OR 'rr' OR 'or' OR 'hazard ratio' OR 'relative risk' OR 'odds ratio'). Only publications with full texts in English were taken into consideration. To avoid potentially missing studies during the primary search, the references of pertinent articles and relevant reviews were also scanned manually. The retrieved literatures were examined in detail to exclude potential duplications or repetitive data.

Study selection {#Sec4}
---------------

Duplicated studies were first excluded, then titles and abstracts were carefully scanned. Next full texts of potentially qualified studies were reviewed. We included studies if they met all the following criteria: (1) the studies of interest were dairy products intake; (2) the studies were population-based cohort studies and reported cancer mortality data; (3) relative risk (RR), hazard ratio (HR) or odds ratio (OR) estimates with 95 % confidence interval (CI) adjusted for multivariable factors were available or could be calculated; (4) original articles with full texts in English. Studies were excluded according to the following criteria: (1) reviews, letters, unpublished data or comments; (2) those published in languages other than English; (3) not population-based cohort studies; (4) RR, HR or OR estimates with 95 % CI were not available or could not be calculated.

Data extraction {#Sec5}
---------------

The study quality assessment was performed according to the Newcastle-Ottawa Scale \[[@CR17]\]. Two reviewers (Dr. Yihua Wu and Dr. Wei Lu) extracted data using a standardized data extraction table independently. Any discrepancy was resolved by a third reviewer. Information extracted from each eligible study included the following items: first author, country, original study design, number of participants, gender, age, follow-up duration, dairy product types, group cut-off value, cancer types, endpoints, adjusted factors and study quality assessment. RR, HR or OR estimates with 95 % CI with regard to different types of dairy products and doses were recorded respectively. The most completely adjusted estimate was extracted if several risk estimates were available.

Data synthesis and statistical analyses {#Sec6}
---------------------------------------

The random-effect model was applied to calculate pooled RRs, 95 % CI and *p* value for heterogeneity. RRs comparing the highest intake category with the lowest intake category were combined across studies to generate the summary associations. The extent of heterogeneity across studies was examined using the I^2^ test \[[@CR18]\] and I^2^ \> 50 % together with *p* \< 0.05 indicated significant heterogeneity. In order to validate the stability of outcomes in the meta-analysis, sensitivity analyses were performed by including studies which only reported all cancer mortality. Sequential omission of each individual study was also performed, while subgroup analyses were carried out to investigate the impact of regions, dairy product types and genders on cancer mortality. Funnel plots were constructed to assess the publication bias, meanwhile the Begg's rank correlation test and Egger's regression test was adopted to test the asymmetry and *p* \< 0.1 indicated statistically significant publication bias \[[@CR19]\].

We then looked for potential dose--response relationship between dairy products intake and cancer mortality risk using the generalized least squares(GLST) method for trend estimation of summarized data \[[@CR20]\]. The doses reported in each study were first converted to servings/day, respectively. Kelemen's study was excluded from dose--response analysis because dairy intakes were reported in densities (servings/1000 kcal). Bonthuis's study was also excluded because dairy intakes were reported in g/day. The average of the lower and upper limits in each category were calculated and recorded as the mid-point dose. For open-ended intervals, we estimated the mid-point dose equaled to 1.5 times the lower limits. A potential curvilinear relationship was assessed using restricted cubic splines with four knots at fixed percentiles (5, 35, 65 and 90 %) of the distribution \[[@CR20]\]. For model verification, we used *χ* ^2^ test and a *p* value for a non-linear relationship was calculated by testing the null hypothesis that the coefficient of the second spline was equal to zero. Non-linear model was applied in the first place if model verification indicated significance (*p* \< 0.05), otherwise linear model was adopted. The dose--response curves containing RRs with 95 % CI for each dairy product type were constructed, respectively. Heterogeneity was tested using I^2^ test and I^2^ \> 50 % together with *p* \< 0.05 indicated significant heterogeneity.

All analyses were conducted using Stata software (version 13.0; StatCorp, College Station, TX, USA), and the significance level was set to *p* \< 0.05 unless specified.

Results {#Sec7}
=======

Literature search {#Sec8}
-----------------

We identified 1031 publications after searching PubMed and 1625 publications in EMBASE. First of all 172 duplicated studies were removed, followed by the exclusion of 2462 studies after reviewing abstracts and titles carefully. After full-text review of the remaining 22 articles, another 11 studies were excluded for the following reasons: six articles provided insufficient data, four only reported cancer incidence risk and one conference article. References of pertinent articles and relevant reviews were also scanned manually. Finally, the remaining 11 studies \[[@CR21]--[@CR31]\] with 778,929 participants were included in the following analyses (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow diagram of the study selection process

Description of the included studies {#Sec9}
-----------------------------------

Characteristics of the included studies were shown in Table [1](#Tab1){ref-type="table"}. In brief, 11 studies were all population-based cohort studies, five were from America, three from Japan, one from Australia, one from Europe and one was multiethnic. However, Wang's study and Kojima's study were all from Japan Collaborative Cohort Study, and Wang focused on the correlation between milk consumption and all cancer mortality, while Kojima focused on the relationship between different types of dairy products consumption and colorectal cancer mortality. In addition, cancer types were various across studies. Dairy product types included total dairy, milk, yogurt, cheese, butter, whole milk and skim/low-fat milk. It was noteworthy that two studies reported prostate cancer, which was further discussed in the subgroup analyses. The quality assessment of each study was performed according to the Newcastle-Ottawa Scale, as shown in Table [2](#Tab2){ref-type="table"}.Table 1Characteristics of the included studiesStudyCountry of originOriginal designNumber of participants (Male/Female)Age (years)Follow-up (years)Dairy products typeGroup cut-off valueBonthuis et al. (2010) \[[@CR21]\]AustraliaCohort663/85625--7814.4Total dairyMean: (163; 339; 628) g/dayBreslow et al. (2000) \[[@CR22]\]AmericaCohort8363/1164118--878.5Total dairy(0--3.0; 3.0--7.0; 7.0--10.0; \>10.0) servings/dayChow et al. (1992) \[[@CR23]\]AmericaCohort17633/0\>3520 (maximum)Total dairy(\<46; 46--95; 96--142; \>142) servings/monthKelemen et al. (2005) \[[@CR24]\]AmericaCohort0/2901755--6915Total dairyMedian: (1.0; 1.13; 1.24; 1.34; 1.45) servings/1000 kcalKojima et al. (2004) \[[@CR25]\]JapanCohort45181/6264340--799.9Milk(seldom; 0.5--4 servings/week; everyday)Yogurt(seldom; 1--2 servings/month; 1--7 servings/week)Cheese(seldom; 1--2 servings/month; 1--7 servings/week)Butter(seldom; 1--2 servings/month; 1--7 servings/week)Matsumoto et al. (2007) \[[@CR26]\]JapanCohort4531/707519--939.2Milk, butter and yogurt(not everyday; everyday)Park et al. (2007) \[[@CR27]\]AmericaCohort293888/050--716 (maximum)Whole milk(0; 0--0.5; 0.5--1; 1--2; \> = 2) servings/dayLow-fat milk(0; 0--0.5; 0.5--1; 1--2; \> = 2) servings/daySkim milk(0; 0--0.5; 0.5-1; 1--2; \> = 2) servings/dayCheese(\<0.1; 0.1--0.25; 0.25--0.5; 0.5--0.75; \> = 0.75) servings/dayYogurt(0; 0--0.5; \> = 0.5) servings/dayPraagman et al. (2015) \[[@CR28]\]EuropeCohort8901/2550820--7015Fermented dairyMedian: (8.8; 52.2; 128; 351) g/dayYogurtMedian: (3.8; 26.2; 62.9; 144.5) g/dayCheeseMedian: (6.6; 19.6; 31.8; 53.2) g/daySharma et al. (2013) \[[@CR29]\]MultiethnicCohort70333/7605645--75NATotal dairy(\<=0.5; 0.6--1.0; 1.1--1.6; \>1.6) servings/daySong et al. (2013) \[[@CR30]\]AmericaCohort21660/040--8428 (maximum)Total dairy(\<=0.5; 0.5--1.0; 1.0--1.5; 1.5--2.5; \>2.5) servings/dayWhole milk(\<=1; 2--6; \> = 7) servings/weekSkim/low-fat milk(\<=1; 2--6; \> = 7) servings/weekWang et al. (2015) \[[@CR31]\]JapanCohort39639/5534140--7919Milk(0; 1--2 servings/month; 1--2 servings/week; 3--4 servings/week; everyday)StudyCancer typeEndpointsAdjusted factorsQuality assessmentBonthuis et al. (2010) \[[@CR21]\]All cancerAll cancer deathAge, sex, total energy intake, body mass index, alcohol intake, school leaving age, physical activity level, pack years of smoking, dietary supplement use, b-carotene treatment during trial and presence of any medical condition9Breslow et al. (2000) \[[@CR22]\]Lung cancerLung cancer deathAge, sex, smoking duration and packs per day smoked8Chow et al. (1992) \[[@CR23]\]Lung cancerLung cancer deathAge, smoking status and industry/occupation8Kelemen et al. (2005) \[[@CR24]\]All cancerAll cancer deathAge, total energy, carbohydrate, saturated fat, polyunsaturated fat, monounsaturated fat, trans-fat total fiber, dietary cholesterol, dietary methionine, alcohol, smoking, activity level, body mass index, history of hypertension, postmenopausal hormone use, multivitamin use, vitamin E supplement use, education and family history of cancer6Kojima et al. (2004) \[[@CR25]\]Colon and rectal cancerColon and rectal cancer deathAge, family history of colorectal cancer, body mass index, frequency of alcohol intake, current smoking status, walking time per day, and educational level9Matsumoto et al. (2007) \[[@CR26]\]Colon, stomach, lung, liver, pancreatic, bile duct and blood cancerColon, stomach, lung, liver, pancreatic, bile duct and blood cancer deathAge and sex9Park et al. (2007) \[[@CR27]\]Prostate cancerProstate cancer death and advanced prostate cancerAge, race, education, marital status, body mass index, vigorous physical activity, smoking, alcohol consumption, history of diabetes, family history of prostate cancer, screening for prostate cancer by use of prostate-specific antigen, intakes of tomatoes, red meat, fish, vitamin E, alpha-linolenic acid and total energy8Praagman et al. (2015) \[[@CR28]\]All cancerAll cancer deathAge, sex, total energy intake, smoking habit, body mass index, physical activity, education level, hypertension at baseline, intakes of alcohol and energy-adjusted intakes of fruit and vegetables9Sharma et al. (2013) \[[@CR29]\]All cancerAll cancer deathTime on study, years of education, energy intake, smoking behaviors, body mass index, physical activity, history of diabetes, alcohol intake, history of hormone replacement therapy, and history of oophorectomy8Song et al. (2013) \[[@CR30]\]Prostate cancerProstate cancer deathAge, cigarette smoking, vigorous exercise, alcohol intake, race, body mass index, baseline diabetes status, red meat consumption, total energy intake from recorded food items, assignment in the original aspirin trial and assignment in the original β-carotene trial. In addition, the models for whole milk and skim/low-fat milk were mutually adjusted for each other8Wang et al. (2015) \[[@CR31]\]All cancerAll cancer deathAge categories, smoking status, drinking status, physical activity, sleeping duration, body mass index, education level, participation in health checkups, green-leafy vegetable intake, and history of hypertension, diabetes and liver disease9 Table 2Quality assessment according to Newcastle-Ottawa ScaleStudyQ1Q2Q3Q4Q5Q6Q7Q8TotalBonthuis et al. (2010) \[[@CR21]\]111121119Breslow et al. (2000) \[[@CR22]\]111121108Chow et al. (1992) \[[@CR23]\]111120118Kelemen et al. (2005) \[[@CR24]\]011120106Kojima et al. (2004) \[[@CR25]\]111121119Matsumoto et al. (2007) \[[@CR26]\]111121119Park et al. (2007) \[[@CR27]\]111121108Praagman et al. (2015) \[[@CR28]\]111121119Sharma et al. (2013) \[[@CR29]\]111121108Song et al. (2013) \[[@CR30]\]011121118Wang et al. (2015) \[[@CR31]\]111121119

Association between total dairy products intake and cancer mortality risk {#Sec10}
-------------------------------------------------------------------------

In each individual study, RRs of the highest total dairy products intake group versus the control group were introduced. For the association between total dairy products intake and all cancer mortality, ten studies except Kojima' study were included and the pooled RR was 0.99 (95 % CI 0.92--1.07, *p* = 0.893), as shown in Fig. [2a](#Fig2){ref-type="fig"}. No significant heterogeneity across studies was observed (I^2^ = 39.8 %, *p* = 0.092). Begg's funnel plot and the Egger's linear regression test were conducted to evaluate publication bias. The shape of Begg's funnel plot showed no evident asymmetry (Fig. [2b](#Fig2){ref-type="fig"}), beyond that Egger's test also suggested no publication bias existed (*p* = 0.947).Fig. 2Total dairy intake and cancer mortality risk. **a** Forest plot of total studies evaluating relative risk of cancer mortality. **b** Begg's funnel plot of total studies evaluating potential publication bias. **c** Sensitivity analysis was performed by including studies which only reported all cancer mortality. **d** Sequential omission of each individual study

Sensitivity analyses were performed by including studies which only reported all cancer mortality (Fig. [2c](#Fig2){ref-type="fig"}), and the pooled RR was 0.99 (95 % CI 0.95--1.03, *p* = 0.679). Sequential omission of each individual study was also performed, as shown in Fig. [2d](#Fig2){ref-type="fig"}, the result pattern was not changed by removing single study each time.

Subgroup analyses {#Sec11}
-----------------

Subgroup analyses were conducted according to different regions, dairy product types and genders. Initially, regions were categorized into America, countries other than America and Asia when we explored the association between total dairy intake and cancer mortality risk. We found the pooled RRs were 0.90 (95 % CI 0.67--1.21, *p* = 0.484) in America, 1.00 (95 % CI 0.95--1.04, *p* = 0.834) in countries other than America and 0.97 (95 % CI 0.92--1.02, *p* = 0.239) in Asia, which was in consistent with the above results.

Dairy product types were then categorized into milk, yogurt, cheese, butter, whole milk and skim/low-fat milk. In both genders, the pooled RRs were 0.97 (95 % CI 0.92--1.03, *p* = 0.314) for milk, 0.88 (95 % CI 0.71--1.10, *p* = 0.271) for yogurt, 1.23 (95 % CI 0.94--1.61, *p* = 0.127) for cheese and 1.13 (95 % CI 0.89--1.44, *p* = 0.317) for butter, proving that intake of these dairy products was not associated with cancer mortality risk significantly (Table [3](#Tab3){ref-type="table"}). However, it was interesting to find that whole milk intake contributed to elevated cancer mortality risk significantly, with the pooled RR of 1.50 (95 % CI 1.03--2.17, *p* = 0.032), which was only limited to prostate cancer. In accordance with this finding, skim/low-fat milk intake was not associated with prostate mortality risk, with the pooled RR of 1.00 (95 % CI 0.75--1.33, *p* = 0.985).Table 3Subgroup analyses according to different dairy product types and gendersMale and femaleMaleFemaleRR95 % CIHeterogeneityRR95 % CIHeterogeneityRR95 % CIHeterogeneityI^2^ (%)*p*I^2^ (%)*p*I^2^ (%)*p*Total dairy0.99(0.92, 1.07)39.80.0921.00(0.91, 1.11)0.00.4221.07(0.96, 1.19)0.00.393Milk0.97(0.92, 1.03)8.40.3510.95(0.89, 1.03)35.10.214NANANANAYogurt0.88(0.71, 1.10)0.00.5210.66(0.42, 1.04)0.00.757NANANANACheese1.23(0.94, 1.61)0.00.9851.19(0.85, 1.67)0.00.912NANANANAButter1.13(0.89, 1.44)1.00.315NANANANANANANANAWhole milk^a^NANANANA1.50(1.03, 2.17)0.00.963NANANANASkim/low-fat milk^a^NANANANA1.00(0.75, 1.33)0.00.735NANANANA^a^cancer type was limited to prostate cancer*NA* Not available

Dose--response analyses {#Sec12}
-----------------------

To begin with, the non-linear model between total dairy products intake and cancer mortality risk was constructed and *χ* ^2^ test was used for model significance verification, which revealed the existence of a non-linear association between them (*χ* ^2^ = 8.98, *p* = 0.030). The dose--response curves containing RRs with 95 % CI and doses were constructed (Fig. [3a](#Fig3){ref-type="fig"}), suggesting that low total dairy products intake may be protective against cancer related death, but high total dairy products intake did not have the same effect.Fig. 3**a** Non-linear and (**b**) linear dose--response analyses for total dairy products intake and cancer mortality risk. Full lines represented RRs and dashed lines represented 95 % CIs

For each dairy type, we adopted the linear model as well to assess RR due to increase of dairy products, which indicated that increase of total dairy, milk, yogurt, cheese, butter or skim/low-fat milk (serving/day) was not associated with elevated cancer mortality risk (Figs. [3b](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"} and Table [4](#Tab4){ref-type="table"}). Nevertheless increase of whole milk (serving/day) contributed to elevated prostate cancer mortality risk significantly, with the RR of 1.43 (95 % CI 1.13--1.81, *p* = 0.003), which was in consistent with the previous subgroup analyses results.Fig. 4Linear dose--response analyses for (**a**) milk, (**b**) yogurt, (**c**) cheese, (**d**) butter, (**e**) whole milk and (**f**) skim/low-fat milk intake and cancer mortality risk. Full lines represented RRs and dashed lines represented 95 % CIs Table 4Dose--response analyses using the generalized least squares (GLST) method by adopting the linear modelMale and femaleMaleFemaleRR per serving increase95 % CIHeterogeneityRR per serving increase95 % CIHeterogeneityRR per serving increase95 % CIHeterogeneityI^2^ (%)*p*I^2^ (%)*p*I^2^ (%)*p*Total dairy1.02(0.99, 1.05)33.80.3341.00(0.97, 1.04)16.70.4051.04(0.99, 1.10)7.70.564Milk1.03(0.99, 1.08)10.20.5121.02(0.97, 1.08)8.70.2751.05(0.96, 1.14)1.20.559Yogurt0.94(0.59, 1.48)5.10.4090.60(0.29, 1.26)2.40.2971.10(0.51, 2.37)0.10.715Cheese1.36(0.90, 2.05)5.30.2601.23(0.76, 1.99)0.40.8231.75(0.79, 3.88)4.30.037Butter1.22(0.87, 1.73)1.20.8730.90(0.45, 1.80)0.10.7381.27(0.60, 2.71)0.10.778Whole milk^a^NANANANA1.43(1.13, 1.81)7.30.200NANANANASkim/low-fat milk^a^NANANANA1.07(0.95, 1.20)0.30.877NANANANA^a^cancer type was limited to prostate cancer*NA* Not available

Discussion {#Sec13}
==========

Since dairy products contain complex nutrient composition and the amount of dairy products consumption is huge in our daily life, a number of studies have pointed out that dairy products may have impact on health issues such as obesity \[[@CR32]\], diabetes \[[@CR33], [@CR34]\], cancers \[[@CR10]\] and coronary heart disease \[[@CR35], [@CR36]\]. However, whether dairy products play a beneficial or detrimental role still remained controversial, largely depending on the types of dairy products and diseases. In view of this, we carried out this meta-analysis to comprehensively explore the association between dairy products intake and cancer mortality risk.

The current analyses showed that higher total dairy, milk, yogurt, butter and skim/low-fat milk intake was not associated with increased cancer mortality risk, while exposure to highest dose of whole milk intake increased about 50 % of prostate cancer mortality risk. By constructing a non-linear dose--response model, we concluded that low total dairy products intake may be protective against cancer related death, however high dose of total dairy products did not have the protective effect. Through a linear dose--response model, we found that increase of whole milk (serving/day) contributed to elevated prostate cancer mortality risk significantly, while other dairy types did not show the same effect. This might be explained by the hypothesis that luxuriant calcium contained in whole milk would increase the risk of prostate cancer by inhibiting the potential anti prostate carcinogenic nutrient 1,25-dihydroxyvitamin D \[[@CR37]\]. Besides, high animal fat intake also contributed to poor prostate cancer mortality after diagnosis \[[@CR38], [@CR39]\]. However, although our meta-analysis shed new light on this issue, more future work remained to be done due to complex components of dairy products.

Our study had several crucial strengths. We conducted this thorough systematic search and applied comprehensive analytical approaches to assess the association between dairy products intake and cancer mortality risk. In addition, the studies we included were all population-based cohort studies of high quality. Furthermore, sensitivity analyses and sufficient subgroup analyses were also conducted to ensure the reliability of this study. Finally, we used a non-linear or linear model to fit the dose--response relationship between dairy products intake and cancer mortality risk. The methods of this study were rigorous and were based on guidelines for conducting the present study.

However, the current study was restricted by several limitations. First, the number of studies involved was relatively small, partly because cancer incidence risk rather than mortality risk was much more widely reported, thus the association between each type of dairy products and every specific cancer mortality risk was not available because of inadequate data. Second, most of the included studies were performed in Asia or America, and the studies conducted in America did not confine their cohorts to certain ethnic groups, hence the conclusions should be taken cautiously for other ethnic populations. We suggested further population-based cohort studies which investigate the association between dairy products intake and cancer mortality in each individual ethnic should be conducted. Finally a few studies reported different doses of highest dairy intake, which was further discussed in the dose--response analysis.

Conclusions {#Sec14}
===========

On the basis of the results above, we confirmed that total dairy products intake was not associated with increased cancer mortality risk in both genders, yet low total dairy products intake even reduced relative risk based on the dose--response analyses. However, whole milk intake in men contributed to elevated prostate cancer mortality risk. Furthermore, the linear dose--response relationship existed between increase of whole milk intake and prostate cancer mortality risk.
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